Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy
- PMID: 30407609
- DOI: 10.1111/bjh.15644
Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy
Abstract
Chimeric antigen receptor-modified (CAR)-T cells have demonstrated impressive results in the treatment of haematological malignancies. However, cytokine release syndrome (CRS) and neurotoxicity are common toxicities which are potentially life-threatening in severe cases. Risk factors for CRS and neurotoxicity identified so far include disease burden, lymphodepletion intensity and CAR-T cell dose administered. Risk-adapted dosing, with lower CAR-T cell doses administered to B-cell acute lymphoblastic leukaemia patients with high marrow blast counts, has been successful at decreasing severe CRS rates in this population. Intervention with therapies, such as tocilizumab and corticosteroids, have been effective at ameliorating toxicity, enabling CAR-T cells to be administered safely to many patients without significantly compromising efficacy. Deeper understanding of the pathophysiology of underlying CRS and neurotoxicity will enable the development of novel approaches to reduce toxicity and improve outcomes.
Keywords: chimeric antigen receptor-modified (CAR)-T cells; cytokine release syndrome; neurotoxicity.
© 2018 British Society for Haematology and John Wiley & Sons Ltd.
Similar articles
-
Toxicities of CD19 CAR-T cell immunotherapy.Am J Hematol. 2019 May;94(S1):S42-S49. doi: 10.1002/ajh.25445. Epub 2019 Mar 6. Am J Hematol. 2019. PMID: 30784102 Review.
-
Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.Expert Rev Hematol. 2019 Mar;12(3):195-205. doi: 10.1080/17474086.2019.1585238. Epub 2019 Mar 18. Expert Rev Hematol. 2019. PMID: 30793644 Review.
-
Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.Curr Res Transl Med. 2018 May;66(2):50-52. doi: 10.1016/j.retram.2018.03.003. Epub 2018 Apr 3. Curr Res Transl Med. 2018. PMID: 29625831 Free PMC article. Review.
-
The influence of CRS and ICANS on the efficacy of anti-CD19 CAR-T treatment for B-cell acute lymphoblastic leukemia.Front Immunol. 2024 Sep 27;15:1448709. doi: 10.3389/fimmu.2024.1448709. eCollection 2024. Front Immunol. 2024. PMID: 39399502 Free PMC article.
-
Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.Expert Rev Clin Immunol. 2019 Aug;15(8):813-822. doi: 10.1080/1744666X.2019.1629904. Epub 2019 Jun 20. Expert Rev Clin Immunol. 2019. PMID: 31219357 Free PMC article. Review.
Cited by
-
Novel lectin-based chimeric antigen receptors target Gb3-positive tumour cells.Cell Mol Life Sci. 2022 Sep 12;79(10):513. doi: 10.1007/s00018-022-04524-7. Cell Mol Life Sci. 2022. PMID: 36097202 Free PMC article.
-
Features and outcomes of patients admitted to the ICU for chimeric antigen receptor T cell-related toxicity: a French multicentre cohort.Ann Intensive Care. 2024 Jan 31;14(1):20. doi: 10.1186/s13613-024-01247-9. Ann Intensive Care. 2024. PMID: 38291184 Free PMC article.
-
[CAR T-cell therapy for children and adolescents with acute lymphatic leukemia].Internist (Berl). 2021 Jun;62(6):597-604. doi: 10.1007/s00108-021-01041-w. Epub 2021 May 5. Internist (Berl). 2021. PMID: 33950273 Review. German.
-
Efficacy of glucocorticoids, chloroquine and vitamin A on cytokine release syndrome: a network pharmacology study.J Tradit Chin Med. 2022 Feb;42(1):116-121. doi: 10.19852/j.cnki.jtcm.2022.01.008. J Tradit Chin Med. 2022. PMID: 35294131 Free PMC article.
-
Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation.Front Immunol. 2022 May 23;13:886546. doi: 10.3389/fimmu.2022.886546. eCollection 2022. Front Immunol. 2022. PMID: 35677038 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
